These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 26273573)

  • 41. Polyester as Antigen Carrier toward Particulate Vaccines.
    Gonzalez-Miro M; Chen S; Gonzaga ZJ; Evert B; Wibowo D; Rehm BHA
    Biomacromolecules; 2019 Sep; 20(9):3213-3232. PubMed ID: 31122016
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51.
    Sanakkayala N; Sokolovska A; Gulani J; Hogenesch H; Sriranganathan N; Boyle SM; Schurig GG; Vemulapalli R
    Clin Diagn Lab Immunol; 2005 Dec; 12(12):1429-36. PubMed ID: 16339067
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Challenges in developing mucosal vaccines and antibodies against infectious diarrhea in children.
    Tokuhara D
    Pediatr Int; 2018 Mar; 60(3):214-223. PubMed ID: 29290097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjuvants and delivery issues related to immunization: a survey of the recent patent literature.
    Mrsny RJ
    J Drug Target; 1998; 6(4):243-9. PubMed ID: 9894692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases.
    Duan Z; Xu H; Ji X; Zhao J
    Future Microbiol; 2015; 10(8):1307-23. PubMed ID: 26234909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Various carrier system(s)- mediated genetic vaccination strategies against malaria.
    Tyagi RK; Sharma PK; Vyas SP; Mehta A
    Expert Rev Vaccines; 2008 May; 7(4):499-520. PubMed ID: 18444895
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine.
    Luke TC; Hoffman SL
    J Exp Biol; 2003 Nov; 206(Pt 21):3803-8. PubMed ID: 14506215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vaccination Strategies against Malaria: novel carrier(s) more than a tour de force.
    Tyagi RK; Garg NK; Sahu T
    J Control Release; 2012 Aug; 162(1):242-54. PubMed ID: 22564369
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RNA based vaccines.
    Cannon G; Weissman D
    DNA Cell Biol; 2002 Dec; 21(12):953-61. PubMed ID: 12573052
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mucosal responses to parenteral and mucosal vaccines.
    Kaul D; Ogra PL
    Dev Biol Stand; 1998; 95():141-6. PubMed ID: 9855424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Innovative Approaches to Improve Anti-Infective Vaccine Efficacy.
    Yeaman MR; Hennessey JP
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():189-222. PubMed ID: 28061685
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Methods to Evaluate Novel Hepatitis C Virus Vaccines.
    Ahlén G; Frelin L
    Methods Mol Biol; 2016; 1403():221-44. PubMed ID: 27076133
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multivalent and Multipathogen Viral Vector Vaccines.
    Lauer KB; Borrow R; Blanchard TJ
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27535837
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel ELISA method as exploratory tool to assess immunity induced by radiated attenuated sporozoites to decipher protective immunity.
    Knepper TA; Duncan EH; Savransky T; Bergmann-Leitner ES
    Malar J; 2017 Nov; 16(1):484. PubMed ID: 29187199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaccine technologies: From whole organisms to rationally designed protein assemblies.
    Karch CP; Burkhard P
    Biochem Pharmacol; 2016 Nov; 120():1-14. PubMed ID: 27157411
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dendritic cell discoveries provide new insight into the cellular immunobiology of DNA vaccines.
    Coombes BK; Mahony JB
    Immunol Lett; 2001 Sep; 78(2):103-11. PubMed ID: 11672594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
    Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution.
    Rey-Jurado E; Tapia F; Muñoz-Durango N; Lay MK; Carreño LJ; Riedel CA; Bueno SM; Genzel Y; Kalergis AM
    Front Immunol; 2018; 9():26. PubMed ID: 29403503
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Animal poxvirus vaccines: a comprehensive review.
    Bhanuprakash V; Hosamani M; Venkatesan G; Balamurugan V; Yogisharadhya R; Singh RK
    Expert Rev Vaccines; 2012 Nov; 11(11):1355-74. PubMed ID: 23249235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.